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Abstract 
Neonatal rodents chronically treated with the tricyclic antidepressant clomipramine 
show depression-like behavior, which persists throughout adulthood. Therefore, this animal 
model is suitable to investigate the pathomechanism of depression, which is still largely 
unknown at the molecular level beyond monoaminergic dysfunctions. Here, we describe 
protein level changes in the prefrontal cortex of neonatally clomipramine-treated adult rats 
correlating with behavioral abnormalities. Clomipramine was administered to rat pups twice 
daily between postnatal days 8-21, while controls received saline injections. Behavioral tests 
were performed on 3 months old rats. The proteomic study was conducted using two-
dimensional differential gel electrophoresis. We have identified 32 proteins by mass 
spectrometry analysis of the significantly altered protein spots. The changed proteins are 
related to several biological functions, such as inflammation, transcription, cell metabolism 
and cytoskeleton organization. Among the altered proteins, the level of macrophage migration 
inhibitory factor showed the largest alteration, which was confirmed with Western blot. 
Macrophage migration inhibitory factor showed widespread distribution and was 
predominantly expressed in astrocytes in the forebrain of rats which were described using 
immunohistochemistry. We conclude that neonatal clomipramine exposure induces sustained 
modification in the proteome, which may form the molecular basis of the observed 
depression-like behavior in adult rats.  
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Biological significance 
It is known that some of the psychiatric disorders, such as autism, depression or 
schizophrenia may be at least in part, developmental disorders. We hypothesized that 
clomipramine treatment in early stage of brain development, which is known to induce 
depression-like behavior in adult rats, results in pathological distortion in neuronal and glial 
network development, which can be reflected by the cellular proteome in adulthood. Thus, we 
performed an unbiased proteomics experiment in adult rats, which were neonatally 
administered with clomipramine to reveal protein level changes three months after treatment. 
Many of the identified changed proteins are previously associated with depressive symptoms, 
e.g., the macrophage migration inhibitory factor (MIF), the level of which showed the largest 
alteration among the identified proteins. Based on our data, we suggest that neonatal 
clomipramine treatment is a reliable model to study the developmental effect of psychoactive 
drugs applied in the sensitive early phase of brain development. Furthermore, our findings 
support the idea that the alteration of early development of the brain induced by 
antidepressant treatment could result in sustained pathological changes in the cellular 
phenotype in the prefrontal cortex leading to depression-like behavioral symptoms.  
 
1. Introduction 
Depression affects millions of people worldwide, as it was rated the fourth leading 
disabling condition in the year 2000 [1], and it is predicted that it would be the second by 
2020 [2]. According to the 5th edition of Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), major depressive disorder (MDD) or clinical depression can be 
diagnosed if the patient meets five of nine symptoms for at least 2 weeks long [3]. However, 
we still lack the proper molecular biomarkers to precisely diagnose the disease. Although 
effective treatments are available, the problem is that not all patients respond to them, most 
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likely because depression is a molecularly heterogeneous disease. Still, most of the obtainable 
and effectively used medications are based on elevation of monoamine levels in line with the 
monoamine hypothesis of depression [4-6]. It is unknown, however, why mood improving 
effects of the medications appear only after several weeks of treatment, and depression cannot 
be initiated by reducing the levels of the monoamines in a healthy subject [7]. A modified 
hypothesis has been postulated that antidepressant medication may alleviate depression 
through the desensitization of 5-HT1A, 5-HT3 and 5-HT7 serotonin receptors [4, 8].  
In contrast to early theories which emphasize the exceptional significance of the 
monoamine systems, depression is actually considered to be the result of complex interactions 
between thousands of genes and multiple environmental risk factors. None of them alone can 
cause depression. Recently, a hypothesis of depression emerged implicating the altered 
neuroplasticity in the disease. Depressed patients show evidence of impaired neuroplasticity 
and antidepressant medications enhance neuroplasticity at both the molecular and the cellular 
level [9]. There is also an inflammatory hypothesis of depression, which is proposed by the 
observation that elevated levels of proinflammatory cytokines are present both in blood 
plasma, and in the cerebrospinal fluid during depressive states in patients [10, 11]. 
Furthermore, sickness feeling after viral or bacterial infection has similar symptoms as 
depression suggesting similarities in their molecular background [12, 13]. However, the 
alterations may not be equally located in the brain. The peculiar role of the prefrontal cortex 
(PFC) in depression has been suggested based on structural and functional neuroimaging [14] 
and lesion studies [15, 16].  
It has been established that neonatal administration of the tricyclic antidepressants in 
rodents provides a well-characterized animal model of major depression. Neonatal rat pups, 
chronically treated with clomipramine or the selective serotonin reuptake inhibitor (SSRI) 
citalopram, demonstrated persistent changes in behavior in adulthood (which phenomenon 
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was named “neonatal antidepressant exposure syndrome” (NADES)) including characteristics 
of depression-like behaviors and changes in sleep pattern of adult rats [17-20]. In the 
clomipramine model, altered expression of 5-HT1A receptor was recently demonstrated, 
which is in accordance with the monoamine hypothesis of depression [21]. It was also shown 
that mammalian target of rapamycin (mTOR) signaling is also compromised in clomipramine 
rat model in accordance with the altered neuroplasticity hypothesis of depression [22]. In 
addition, we previously demonstrated that neonatal clomipramine treatment aggravated the 
depression-like symptoms in WAG/Rij rats (a genetic rat model of absence epilepsy), and 
decreased their epileptic activity [23]. Although, the neurobiological processes behind 
NADES are unknown, antidepressant administration of rats during their highly-sensitive brain 
development period could model the long-term detrimental effects of depression in general, 
and specifically the maternal antidepressant medication on developing fetuses or neonate 
children [24]. Therefore, we addressed the question whether there is a detectable phenotype 
modifiation in cells of the PFC in the clomipramine model of depression [15, 16, 25, 26].  
 
2. Materials and methods 
2.1. Animals 
Wistar rats (Toxi-Coop, Budapest, Hungary) were housed under standard laboratory 
conditions (12:12 h light:dark periods, light was on from 8.00 am to 8.00 pm) at a constant 
temperature of 22 ± 2 ºC. Food and water were supplied ad libitum. The care and treatment of 
all animals conformed to Hungarian Act of Animal Care and Experimentation (1998, XXVIII) 
and to the guidelines of the European Communities Council Directive, 86/609/EEC as well as 
with local regulations for the care and use of animals for research. 
 
2.2.  Experimental design 
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Six litters of rats were used for the experiments. We have taken account the mortality 
caused by the clomipramine treatment, therefore on postnatal day (PD) 8, we randomly 
assigned 3-4 female pups per litter for chronic clomipramine treatment (CLO) and the rest of 
the females were received vehicle (physiological saline solution) injections (control, C). From 
PD 8 to 21 of age, all experimental animals were treated twice a day (between 8.00-9.00 a.m. 
and 6.00-7.00 p.m.) as follows: CLO-rats received clomipramine (20 mg/kg, subcutaneously) 
(Sigma–Aldrich, Germany) dissolved in 700 µl saline and the control group received saline in 
the same volume. The weight of animals was monitored throughout the chronic clomipramine 
administration. Surprisingly, there was no significant alteration between the control and 
clomipramine treated groups. At 30 days of age, offspring were separated from their mothers. 
Three-four gender-matched rats per cage were housed together until the behavioral tests. The 
gender-related differential responses to clomipramine treatment in rat model were 
investigated by behavior tests before [27]. Kokras et al. found relevant behavioral responses 
and elevated serotonin turnover rate in both genders. However, they revealed that the effect of 
antidepressant administration was more pronounced in females. Based on these findings 
female rat pups were used in our experiments. 
 
2.3. Forced swim test 
We used the forced swim test (FST) procedure to test the depression-like behavior of 
rats. The FST is a widely accepted, frequently used test for investigating depression-like 
behavior in rodents [28, 29]. It could have been very useful to test anhedonia in addition to the 
learned helplessness and correlate the two trait signs of depression-like behavior, without the 
necessity to use additional tests which could pose significant stress affecting the subsequent 
molecular experiment. The FST procedure involves the scoring of active (swimming and 
struggling) or passive (immobile floating) behaviors while the subjects are placed in a water-
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filled cylinder from which escape is not possible. The latency and duration of passive 
behavior called here floating are informative on the learned helplessness of the animals [30].  
A total of 20 rats (n = 10 in each group) at 3 months of age (270-300 g) were used in 
the experiments. The apparatus used in the present study was a clear rectangular glass 
cylinder with dimensions of 30x30x50 cm (width x depth x height) which was filled with 
lukewarm water (26-28 °C) to the height of appx. 20 cm, thus the animal could not 
comfortably rest his hindlegs at the bottom. The apparatus was put in sound attenuated, dimly 
lit experimental room with controlled ambient temperature conditions (24 °C). Each test 
sessions were held in the mornings between 9:00 am and 12:00 am. Test sessions were lasted 
for 5 min and were repeated three times, once on each of the three consecutive test days to 
ensure the stability of the observed trait behavioral signs. The cylinder was cleaned between 
rats and was emptied and re-filled when required during the test sessions. All subjects were 
tested in the same order. One hour before the test sessions begun, the animals were 
transported to the test room on a rack, and were accommodated in an enclosure close to the 
testing apparatus. The FST test sessions were continuously video-recorded from the side of 
the cylinder. Video recordings were scored off line by two independent raters. Inter-rater 
reliability (measured with Cohen’s kappa) values for the three dependent variables in the two 
conditions fell in the fair-to-good range (between 0.61 and 0.7) [31].The mean of the scores 
were used as processed data. Latency to reach passive floating behavior (immobility) was 
defined as the time at which the rat first initiated a stationary posture that did not attempt to 
escape. In this characteristic posture, the forelimbs were motionless and tucked toward the 
body with the head kept out of the water. To qualify as immobility, floating had to be present 
for at least 2 s. In addition to immobility latency data, the total time spent with the passive 
floating behavior was also computed. Statistical tests were performed using R for Windows 
3.2.3 (R Core Team, 2016. R: a Language and Environment for Statistical Computing. R 
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Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.)  Shapiro-
Wilk test was performed to check normality of variables. Because non-normal distribution 
was found (p<0.05) we used Brunner-Munzel test of the R package “lowstat” v.3.0.”  
 
2.4. Proteomics experiment 
2.4.1. Preparation of tissue samples and the 2-D DIGE method 
One week after the behavioral tests, rats (6 control and 6 CLO treated) were deeply 
anaesthetized with intraperitoneal urethane administration. Their brains were quickly removed 
from their skulls and were placed in dry ice-cooled artificial cerebrospinal fluid. Prefrontal 
cortices were dissected immediately and the samples were stored at -80 °C.  
The proteomic analysis was performed using two-dimensional differential gel 
electrophoresis (2-D DIGE) Minimal Dye Labeling method. All equipment, materials and 
softwares were supplied from GE Healthcare, Little Chalfont, UK. The detailed 2-D DIGE 
protocol has been described in our earlier study [32]. In briefly, brain samples were 
homogenized and their protein concentrations were determined using a 2-D Quant Kit. 
Samples, containing 50 µg protein amount from three CLO and three C rats were labeled with 
Cy3 and Cy5 dyes randomly, and the other half of the samples were labeled conversely. The 
reference sample (pooled internal standard, which comprises equal amounts of protein from 
all biological samples in the experiment) was labeled with Cy2 dye. The differently labeled 
samples from randomly paired CLO and C rats and equal amounts from the reference sample, 
were multiplexed and subjected for electrophoresis. Samples were dissolved in isoelectric 
focusing (IEF) buffer containing ampholytes and rehydrated passively onto 24 cm NL IPG 
strips overnight. After rehydration, the IPG strips were subjected to first dimension IEF for 24 
h to attain a total of 80 kVh. Subsequent to IEF, the gels were equilibrated in reducing 
conditions, then the proteins were carbamidomethylated for 20-20 min, respectively. After 
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equilibrations, the IPG strips were loaded onto 10% polyacrylamide gels (24×20 cm), and 
SDS-PAGE was conducted at 2 W/gel for 1 h and at 12 W/gel for 3 h in the second dimension 
using an Ettan DALT Six System. Following electrophoresis, gels were scanned in a Typhoon 
TRIO+ scanner using appropriate lasers and filters with the photomultiplier tube was biased at 
600 V. The gel images were visualized using the Image Quant software. Quantitation of 
fluorescence intensities of the protein spots and statistical analyses (independent, two-tailed 
Student’s t-test) were performed using the DeCyder 2-D Differential Analysis Software 
package (GE Healthcare, Little Chalfont, UK). The used fluorescent labeling technology and 
software analysis enable identification of strikingly low-level protein abundance differences 
(less than 10%) with more than 95% confidence [33]. Therefore, the cut-off of ± 1.1-fold 
change in fluorescence intensity of matched protein spots between experimental groups was 
applied in the current study. 
For the identification of proteins in spots of interest, preparative 2-D gel 
electrophoresis was carried out separately using a total of 800 µg of proteins. Proteins were 
stained with Colloidal Coomassie Brilliant Blue G-250 (Merck Millipore, Darmstadt, 
Germany). The significantly altered protein spots were manually excised from the preparative 
gel and were stored in 1% acetic acid solution until the mass spectrometry (MS) analysis. 
 
2.4.2. Protein identification using mass spectrometry (LC-MS/MS) 
Excised protein spots were in-gel digested for MS-based protein identification, using 
the protocol provided by the UCSF Mass Spectrometry Facility (University of California, San 
Francisco, San Francisco, CA, USA) and, which is available online at: 
http://msf.ucsf.edu/protocols.html. Briefly, after dithiothreitol reduction and iodoacetamide 
alkylation, the proteins were digested with trypsin (sequencing grade modified trypsin from 
pig pancreas, Promega, Madison, WI, USA). Peptides were subjected to LC-MS/MS analysis 
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on an LCQ-Fleet iontrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA), 
on-line coupled with a nano-Acquity HPLC system (Waters Corporation, Milford, MA, 
USA). Five µl out of the 10 µl peptide extracts were injected to the nano-HPLC system, using 
a trap column (Symmetry C18, 0.18×20 mm, 5 µm, Waters Corporation) and analyzed on a 
BEH300 C18 1.7 um (0.1 × 100 mm) nanoAcquity UPLC Column (Waters Corporation), 
using a gradient elution (10-40 % of B in 30 minutes; B: 0.1 % formic acid in acetonitrile; A: 
0.1 % formic acid in water). MS data were acquired in a data-dependent mode, using triple 
play method. Each survey scan was followed by zoom scans and collision-induced 
dissociation (CID) scans (normalized collision energy: 35) of the three most abundant 
multiply charged precursor ions. Dynamic exclusion was set to 30 s. Mascot Distiller software 
(version 2.2.1.0,  Matrix Science Inc., London, UK) was used to generate the MS/MS peak 
list files from the raw data, and ProteinProspector  (version 5.3.0.)  search engine for database 
search. The parameters were set as follows during the search in the latest UniProt database 
(http://www.uniprot.org, Swiss Institute of Bioinformatics, Switzerland). The searching was 
conducted with settings as follows: taxonomy: Rattus norvegicus; enzyme: trypsin (two 
missed cleavage sites were allowed); fixed modifications: carbamidomethylation; variable 
modifications: acetylation (protein N-terminus), Gln to pyro-Glu (N-terminus Q), oxidation; 
peptide mass tolerance: ± 0.6 Da; fragment mass tolerance: ± 1 Da. Proteins, identified at 
least with two unique peptides were considered as valid hits. 
 
2.4.3. Functional clustering of identified proteins and bioinformatic analysis 
Based on the UniProt database and on an extensive literature search, functional 
clustering of proteins was performed. For detailed protein interaction modeling analysis, 
Pathway Studio 9.0 software (Ariadne Genomics, Inc., Rockville, MD, USA) was used. The 
pathways were created based on expression regulation between the proteins. We selected 
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common regulator proteins that have minimum 3 relations with significantly changed proteins 
from the experimental results and connected with MIF for further analysis. In the common 
target pathway we included targets which have relations with MIF. The created protein 
network model was manually verified using thorough literature mining. 
 
2.5. Western blot 
The proteins of homogenized PFC tissues were precipitated using chloroform and 
methanol [34]. Subsequently, samples (n = 4 in each group) were resuspended in lysis buffer, 
and were assayed for protein concentration using 2-D Quant Kit. Thirty-five micrograms of 
proteins were separated using Tricine-SDS-polyacrylamide gel electrophoresis on 15% 
polyacrylamide gels, and then proteins were transferred to Hybond-LFP polyvinylidene 
difluoride (PVDF) transfer membranes (GE Healthcare). The gels were stained with 
Coomassie Brilliant Blue R-250 (Merck Millipore) and the total protein amount was precisely 
determined for each lane based on their densities. The membranes were blocked with 5% 
bovine serum albumin (BSA) in Tris-buffered saline with 0.1% Tween-20 (TBS-T), and 
incubated with rabbit anti-MIF primary antibody (Abcam, Cambridge, UK, cat. number: 
ab7207) in 1:1,500 dilution in TBS-T, overnight. Subsequently, the membranes were 
extensively washed in TBS-T, followed by incubation with ECL Plex Cy5-conjugated anti-
rabbit IgG secondary antibody (1:2,500 dilution, GE Healthcare). After consecutive washing 
steps in TBS-T, and then in TBS, the protein bands on the blots were visualized using a 
Typhoon TRIO+ scanner. Fluorescence intensities were quantified using ImageJ software 
(NIH, Bethesda, MD, USA). Fluorescence intensity values were normalized to the 
densitometric values of their corresponding Coomassie Brilliant Blue R-250-stained lanes, 
which eliminated errors due to unequal protein loading. Differences between the normalized 
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values from CLO and C samples were statistically analyzed using independent, two-tailed 
Student’s t-test in OriginPro 9.0 (OriginLab Corporation, Northampton, MA, USA). 
 
2.6. Double immunohistochemistry labeling for MIF with NeuN and S100 
The removed brains (n = 4 in each group) were transferred to phosphate buffer (PB) 
containing 20% sucrose for 2 days for cryoprotection and were frozen before sectioning. 
Serial coronal brain sections were cut at 40 μm on a freezing microtome. Sections were 
collected in PB containing 0.1% sodium-azide and stored at 4 ºC. Free floating tissue sections 
were processed for immunolabeling. First, the sections were treated with 3% BSA, 0.5% 
Triton-X 100, 0.05% sodium azide dissolved in PB, followed by washes in PB. Every fourth 
tissue section was immunolabelled with mouse anti-NeuN as a marker of neurons (1:500 
dilution; Millipore, Billerica, MA, USA, cat. number: MAB377) or mouse anti-S100 as a 
marker of astrocytes (1:10,000; Sigma-Aldrich, cat. number: S2532) for 24 h. Subsequently, 
Alexa Fluor 594 donkey anti-mouse secondary antibody (1:500; Molecular Probes, Eugene, 
OR, USA) was applied for 1 h. All of the sections were then incubated with rabbit anti-MIF 
(1:40; Abcam) for 48 h, followed by incubation with biotinylated donkey anti-rabbit 
secondary antibody (1:1,000; Jackson Immunoresearch, West Grove, PA, USA) for 1 h and 
with ABC complex (1:500; Vector Laboratories, Burlingame, CA, USA) also for 1 h. Sections 
were subsequently incubated with FITC-tyramide (1:8,000) and H2O2 in 0.05 M Tris-
hydrochloride buffer, pH 8.0, for 6 min. After washes, the sections were mounted on slides 
and coverslipped with Aqua-Poly/Mount medium (Polysciences Inc., Warrington, PA, USA). 
 
2.7. Microscopy and image processing 
The sections were examined using an Olympus BX60 light microscope in both dark-, 
and bright-field modes. Images were captured at 2,048 x 2,048 pixel resolution using a SPOT 
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Xplorer digital CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA), equipped 
with a 4x objective. The contrast and sharpness of the images were adjusted using the 
‘‘levels’’ and ‘‘sharpness’’ commands in Adobe Photoshop CS 8 (Adobe Systems, San Jose, 
CA, USA). The confocal microscopy examination was conducted with a Nikon Eclipse E800 
microscope (Nikon Corporation, Tokyo, Japan) equipped with Bio Radiance 2100 Laser 
Scanning System (Bio-Rad Laboratories, Hercules, CA, USA) using a 63x objective. Images 
were captured at 1,024 x 1,024 pixel resolution with 2 µm optical thickness. Full resolution of 
the images was maintained until the final figures were assembled, at which point, the images 
were adjusted to a resolution of 300 dpi. 
 
3. Results 
3.1. Depression-like behavioral effect of neonatal clomipramine treatment 
Within the FST session CLO rats had a higher tendency (as compared to controls) to 
make only those movements necessary to keep their heads above water, and showed increased 
immobility (floating) as a sign of depression-like trait behavior. The rats from the C group 
spent 88.1 ± 8.0 s with floating, 97.9 ± 8.1 s with swimming, and 114.0 ± 8.9 s with 
struggling. The animals in the CLO group spent 131.5 ± 9.1 s with floating, 81.0 ± 8.1 s with 
swimming, and 87.5 ± 7.4 s with struggling (Figure 1). According to the statistical analysis, 
the average time spent with floating was significantly elevated in the CLO group (p < 0.001) 
in comparison with the C group, while the average time spent with struggling was 
significantly reduced due to the treatment (p < 0.05).  
 
3.2. Protein level alterations 
The 2-D DIGE proteomics technology was used to investigate the differences in the 
pattern of protein level changes in the PFC of neonatally clomipramine-treated adult rats in 
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comparison with controls. After exclusion of false spots via rigorous manual validation, 927 
spots were accepted on the gels, of which 33 were significantly changed (p < 0.05) with 
higher than ±1.1-fold difference between the control and treated groups. A representative 
image of a gel is shown in Figure 2. Twenty-four of these spots were reliably excised from the 
preparative gel for further protein identification. The HPLC-MS/MS analysis revealed a total 
of 32 different proteins in the spots (Table 1 and 2, Supplementary Table 1). Out of them, 18 
showed increased, while 14 showed decreased abundance levels in the CLO in comparison 
with the C group. Among the identified proteins, aconitase 2 (ACO2) and 
dihydropyrimidinase-related protein 2 (DPYSL-2) were found in more than one spots, which 
could be explained by their potential post-translational modifications, their cleavage by 
enzymes or the presence of their different protein species. 
 
3.3. Clustering of the altered proteins 
Based on the functional analysis of the altered proteins, different processes of the 
cellular metabolism (such as tricarboxylic acid cycle, phosphocreatine, carbohydrate, glucose 
and purine nucleoside metabolism) were affected the most by the clomipramine treatment 
(Figure 3). In addition, significant changes were observed in the levels of proteins, which play 
essential regulatory role in transcription and translation of proteins, cytoskeletal organization, 
regulatory functions such as differentiation and ion homeostasis, stress response (chaperones), 
proliferation, and immune response.  
According to their localization, most of the identified proteins are present in the 
cytoplasm. Others could be found in the nucleus, membrane, mithochondria, extracellular 
space or in various combinations of the above-mentioned cellular components (Figure 4).  
 
3.4. Pathway analysis 
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The result of the pathway analysis is shown in Figure 5. Common expression regulator 
analysis has revealed 10 proteins connected to MIF (Figure 5A). Eight other proteins with 
changed levels (DPYSL2, GAPDH, GSTA2, HOMER1, HSPA8, PGK1, TPI1, and TXN) are 
also connected to these common regulators. Based on our analysis, MIF has 27 common 
targets, which are also connected to at least one other altered protein (Figure 5B). Among the 
changed proteins, GAPDH, HSPA8, PGK1, and TXN are connected to one or more targets of 
MIF. Interestingly, TXN regulates 23 proteins from the 27 MIF-regulated ones.  
 
3.5. Confirmation of the increase in the level of MIF 
The change in the level of MIF described in the proteomics experiment was validated 
using Western blot technique. This protein was chosen because it showed the largest 
difference between the two experimental groups (1.65-fold elevation in CLO rats) in the 
proteomics investigation (Table 1). The Western blot experiment verified our proteomic 
result, because the alteration in the level of MIF was 1.63 ± 0.52-fold increase (p < 0.05) in 
the CLO group in comparison with the controls as shown in Figure 6. In the Western blot 
analysis, the detected protein band at approximately 12.5 kDa corresponds to the monomeric 
form of MIF.  
 
3.6. Localization of MIF in the PFC 
Immunolabeled cell bodies as well as proximal processes appeared in the PFC. The 
distribution of the labeled cells was similar in all parts of PFC. On the other hand, layer-
specific differences were observed in the density of labeled cells, because MIF-
immunoreactive (MIF-ir) cells were particularly abundant in layer I. This distribution 
resembled to that of the astrocytes and was indeed very similar to that of S100-ir cells (Figure 
7). Double immunolabeling revealed that MIF co-localized mainly with astrocytes, and in 
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fact, most of the S100-ir cells were MIF-positive as well. In addition, a few NeuN-positive 
neurons were also positive for MIF, however, these particular cells accounted only for a very 
low portion of the NeuN-ir neurons. Accordingly, the general distribution pattern of MIF-ir 
and NeuN-ir cells was visibly different, for example, neurons are scarce in layer I where MIF-
ir cells were most abundant. The neurons double labeled with MIF and NeuN were relatively 
evenly distributed. Furthermore, immunohistochemistry demonstrated no difference in the 
distribution of MIF-ir cells between the CLO and C groups. 
 
4. Discussions 
We report here on the changes in molecular phyenotype in prefrontal cortical cells of 
rats subjected to neonatal clomipramine treatment to induce depression-like symptoms in 
adulthood. The detected depression-like behavior in the treated rats confirmed the previously 
reported behavioral effects, a pronounced immobility in the FST [35, 36]. The amount of 
proteins with altered levels in the adult PFC in response to neonatal clomipramine treatment 
proves that the treatment induced long-term alterations at the level of the proteome. The 
altered proteins belong to several functional groups suggesting that different cellular 
processes are involved in the neonatally applied clomiparamine model of depression. It has to 
be noted that the observed changes are not necessarily induced by clomipramine treatment 
directly. Rather, clomipramine initiated cellular processes in early development of the 
neonatal brain, which probably gradually developed to the observed changes in adult mature 
phyenotype of PFC cells. 
 
4.1. Energy metabolism 
Four proteins with significantly altered levels can be linked to glycolysis. The level of 
galactokinase (GALK1) was higher in the CLO than in the C group. This enzyme converts 
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galactose to galactose-1-phosphate, therefore, the latter can enter the process of glycolysis. 
Additional steps in glycolysis might be also particularly important because the levels of 
different enzymes, involved in the glycolytic process, were altered. The level of 
triosephosphate isomerase (TPI1) was increased, while that of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and phosphoglycerate kinase (PGK1) have been reduced in the 
CLO group. These findings strongly suggest that depression-like symptoms in this animal 
model are linked to changes in the metabolic activity of the PFC.  
Reduction in the level of the mitochondrial aconitase 2 (ACO2) protein has been 
found in two spots, in addition to the decrease in the amount of pyruvate dehydrogenase 
(PDHA1). These proteins play pivotal roles in the tricarboxylic acid cycle. The expression of 
these metabolic proteins have been found to change in rats following learned helplessness and 
antidepressant treatment [37]. An increase in the level of malate dehydrogenase (MDH1) in 
our experiment is also in agreement with the results of a previous proteomic investigation 
conducted on MDD patients [38]. 
The level of NADH dehydrogenase (ubiquinone) Fe-S protein 8 (NDUFS8) was 
reduced, while that of ATP synthase (ATP synthase, H
+
 transporting, mitochondrial F1 
complex, gamma polypeptide 1) (ATP5C1) was increased upon the treatment. These two 
proteins are linked to energy production and restoration through their function in oxidative 
phosphorylation. Thus, their altered level in the CLO depression model suggests that energy 
production may be affected in depression. Indeed, chronic administration of the tricyclic 
antidepressant imipramine in rats resulted in altered respiratory rates and increased ATP 
synthesis in brain mitochondria [39]. The significance of the correlation between 
mitochondrial functions and MDD has been emphasized recently [40, 41], and our results are 
consistent with this correlation. 
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The level of creatine kinase b (CKB), another protein involved in energy homeostasis, 
was elevated in the CLO group. Notably, CKB produces phosphocreatine, an important 
mobilizable energy supply for the brain. The literature related to association between CKB 
levels and depression is controversial in some aspects. The increase in the level of CKB in the 
serum of non-psychotic major depression patients had been revealed previously in comparison 
with other types of depression syndromes [42], and in the serum of bipolar disorder patients in 
manic phase [43]. The activity of this protein was also increased in the PFC of rats after 
chronic treatment with the antidepressant paroxetine [44]. On the other hand, both isoforms of 
creatine kinase have been found to be downregulated in the dorsolateral prefrontal cortices of 
bipolar disorder patients [45]. 
In addition, the level of CKB in serum has been used as a biomarker to differentiate 
between psychotic and non-psychotic depression patients on a molecular basis [42]. 
Glutathione transferase (GST) the level of which was increased following to 
clomipramine treatment acts as a coenzyme and antioxidant. Of importance, the PFC of 
schizophrenia and MDD patients showed a reduced level of a protein species of GST 
indicative of a lowered detoxifying capability and an increased susceptibility to oxidative 
damage and suggesting GST protein as target for mood stabilizers [46]. Accordingly, it has 
been demonstrated that particular mood-improving treatments elevate the expression level and 
activity of GST [47, 48]. 
Alterations in the metabolic activity related to depression have been described in 
previous studies in other depression models as well [49, 50]. This correlation was supported 
by our findings, as we found alterations in a number of novel and previously described 
metabolic protein in relation to depression.  
 
4.2. Cytoskeleton 
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F-actin-capping protein subunit beta (CAPZB) showed elevation in CLO group, which 
protein’s function is capping of the actin filaments, and thereby, the regulation of the actin 
cytoskeleton. Reduction of DPYSL2, a protein that affects cytoskeletal organization and axon 
guidance, was also found in three different spots. The levels of two other proteins, septin 11 
(SEPT11) and translationally controlled 1 tumor protein (TPT1), involved in cytoskeleton 
regulation, were reduced. These protein level alterations suggest modification of the 
microfilament structure, which is strongly related to synaptic plasticity. Indeed, one of the 
recent trends in psychiatric disease research is the investigation of associations with synaptic 
and cytoskeletal plasticity [51, 52]. Alteration in the expression of cytoskeletal proteins, e.g., 
β-actin was reported by the influence of stress or antidepressant medication [53]. Elevation in 
the levels of tubulin protein species was found, which proteins are main components of the 
cytoskeletal system. The difference between the positions of tubulin isoforms identified in our 
study (at the ~30-40 kDa range) and their theoretical molecular weights at ~50 kDa suggests 
that certain posttranslationally modified forms of the tubulins have been found. The 
posttranslational modification of the alpha form was also observed previously, which could 
play a pivotal role in stress-related mechanisms through regulating neuronal plasticity as 
studied in the hippocampus [54]. The link between stress-induced microtubule changes and 
depression is also strengthened by the fact that acute and/or chronic antidepressant treatment 
can affect the microtubular dynamics [55]. Interestingly, treatment with the antidepressant 
escitalopram decreases the dynamics of microtubule system in the hippocampus [56, 57]. Our 
results in CLO animals, and the above-mentioned previous reports suggest cytoskeletal 
disturbances behind depression-like behavior [58]. Furthermore, we identified several 
proteins, which could be involved in the cytoskeletal rearrangement in depression. 
 
4.3. Transcription and translation 
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Several proteins involved in transcription and translation have been implicated in 
depression diseases [9]. In our experiment, transcription elongation factor b (TCEB2) showed 
an elevated, while eukaryotic translation initiation factor 4H (EIF4H) and the large ribosomal 
protein (RPLP2) showed a reduced level as late results of the neonatal antidepressant 
treatment. Our results suggest that these three proteins may be involved in regulation of 
altered gene expression in depression, which is their first implication in that regard. 
 
4.4. Stress response  
The heat shock cognate 71 kDa protein (HSPA8) showed elevation, while the stress-
70 protein (HSPA9) showed reduction in their levels in the CLO rats. The HSPA8 has a 
function in RNA splicing, and also in protein folding, as does HSPA9, which also plays a role 
in the regulation of cell proliferation. From the heat shock protein family, HSP70 was recently 
correlated to depression in patients with ulcerative colitis, and suggested to be used as a 
biomarker of the psychosomatic features of this disease [59]. Furthermore, the HSP70 coding 
genes were associated with the response to antidepressants in mood disorders [60]. In a mouse 
model of depression, genes related to mitochondrial unfolded protein response, such as 
HSPA9 were found to be correlated with depression-like behavior [41]. Stress-induced-
phosphoprotein 1 (STIP1) acting on folding of proteins, was altered in our study, such as in a 
previous study on depression patients [61]. The level of two proteins, implicated in response 
to oxidative stress, namely thioredoxin (TXN) and homer 1 (HOMER1), were also elevated in 
our model, which is the first evidence for their potential involvement in depression. Overall, 
the results, together with previous literature data suggest an altered cellular stress in some 
brain cells during depression.  
 
4.5. Common regulators and targets of the significantly altered proteins in CLO rats 
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Two pathways were built, comprising the altered proteins, based on the analyses 
performed using Pathway Studio. According to the first pathway, focusing on the common 
expression regulators of the altered proteins (Figure 5A), we can conclude that certain 
cytokines have roles in connecting the altered proteins to each other. These cytokines are 
interleukin-1 beta (IL1-β), which links three of the proteins, namely MIF, glutathione S-
transferase alpha-2 (GSTA2), and TPI1 and tumor necrosis factor (TNF-α) by regulating MIF, 
TXN, GAPDH and also HSPA8 expression. This finding emphasizes that some cytokines 
might represent future drug targets in the development of novel antidepressant medication as 
highlighted previously [10, 62, 63]. Among other common regulators, some general protein 
expression regulators were also found, such as cyclic AMP-responsive element-binding 
protein 1 (CREB1), transcription factor Sp1 (SP1), CCAAT/enhancer-binding protein alpha 
(CEBPA) and mitogen-activated protein kinase 1 (MAPK1). It is also suggested that proteins 
implicated in basic cell metabolism, such as insulin (INS) could have affected the expression 
of the changed proteins.  
The second pathway was constructed on the basis of common targets of the altered 
proteins (Figure 5B). Interestingly, there were few common targets of the altered proteins. 
Therefore, we focused on MIF, a protein, which showed the largest increase in the CLO 
group. MIF shared a large number of targets with thioredoxin (TXN), in addition TXN can 
regulate the expression of MIF, as well. These findings indicate that MIF and TXN participate 
in common regulatory functions. Specifically, both contribute to the expression changes of 14 
different chemokines and cytokines. This observation underlie again the important roles of 
members of the immune system in our animal model of depression. The second largest group 
of proteins, which are regulated by both MIF and TXN, have functions in apoptosis and / or 
cell growth (n = 11). In addition to TXN, MIF also has some common targets with PGK1 as 
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both regulate matrix metalloproteinases (n = 2) functioning in a broad range of biological 
processes. 
 
4.6. MIF, hypothalamic-pituitary-adrenal axis and inflammation 
The MIF showed the largest change, a 1.65-fold increase among the altered proteins in 
the CLO group, which was also validated by western blotting. Macrophage migration 
inhibitory factor is a proinflammatory cytokine, with functions in inflammation, apoptosis, 
metabolic and neuroendocrine processes [64]. This protein can be linked to depression as part 
of the inflammatory hypothesis of the disease, which comes from the finding that in 
depressive states, elevated levels of proinflammatory cytokines can be measured both in the 
plasma and cerebrospinal fluid [10, 11], and that anti-inflammatory treatments can exert 
antidepressant effect [65]. Interestingly, others also associated MIF level alterations with 
depressive and anxiety symptoms [66-68]. In addition, a 1.4-fold increase was described in 
the levels of MIF in the serum of the high-depressive symptoms group compared to the low 
depressive group[67]. Furthermore, MIF also reduces glucocorticoid (GC) sensitivity, which 
has been associated with dysphoric states including depression [69-71]. The ability of 
cytokines to decrease GC sensitivity in immune cells has been described for MIF and 
interleukin-1 in vitro, and has been only shown for MIF in vivo [67, 72, 73]. These findings 
could be linked to the functions of the hypothalamic-pituitary-adrenal axis (HPA) as animals 
of the clomipramine model of depression show cortisol hypersecretion as a consequence of a 
hyperactive HPA axis [74]. Studies from as far as the 1990’s implicate the dysregulation of 
the HPA axis and the dysfunction of the negative feedback loop of the HPA axis in depression 
[75]. In the frontal cortex, elevated corticotropin-releasing factor (CRF) level in depression 
caused a reduction in the CRF receptor binding sites [76], further supporting the link between 
depression and abnormal function of the HPA axis. Since we found only one cytokine, which 
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changed significantly among the altered proteins, MIF could even be one of the main 
mediators of the HPA axis dysfuntion observed in the clomipramine model of depression. Of 
interest, MIF could also regulate a plethora of cytokines as it has been revealed in our 
pathway analysis (Figure 5B). It is possible that clomipramine acutely elevated the levels of 
cortisol or induced anti-inflammatory cytokine secretion (e.g., interleukin-10 in the serum), as 
described before [77], and our finding on the elevated level of MIF represents a long-term 
compensatory mechanism against the triggered changes by adulthood. 
Macrophage migration inhibitory factor has a wide distribution in the adult rat brain, 
as described by Bacher et al., 1998 [78]. Strong immunostaining signal was detected 
previously throughout the brain (e.g., in the pons, cerebellum, hippocampus, and axons of 
neurons in the supragranular layer of the cortex) and also in a diffuse pattern in the cortex, 
which predicted that glial cells are also positive for MIF [78]. These findings are in 
accordance with our present results, as we also found strong MIF labeling in the PFC. 
Increasing evidence supports that the PFC is important regarding to the HPA axis, since it 
regulates the HPA response to stress [79], and may also play a role in the glucocorticoid 
feedback inhibition [80]. In our present study, MIF was predominantly found in astrocytes, 
and only a smaller proportion could be identified in neurons. In the Borna Disease Virus 
infected rat brain, accumulation of MIF in astrocyte end-feet at the blood-brain barrier was 
found, which correlated with reduced number of infiltrating macrophages [81]. These findings 
suggest that MIF in astrocytes could play a role in the modulation of the 
macrophage/microglia response. 
However the function of MIF in the central nervous system is largely unknown, there 
are receptors of it, such as CD44, CD74, CXCR2 and CXCR4. The presence of these 
receptors suggest some alternative mechanism of action as they are found on neural 
stem/progenitor cells as well. It was shown that MIF promotes neural stem/progenitor cell 
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self-renewal, and the neuronal differentiation via the WNT/β-catenin pathway in vitro [82]. It 
was also revealed in cultured neurons that MIF acts as a chaperone for mutant superoxide 
dismutase (SOD1), and can directly inhibit this protein’s misfolding, accumulation and 
association with mithochondria and endoplasmatic reticulum [83]. 
 
5. Conclusions 
Neonatal clomipramine treatment causes depression-like symptoms as it was 
demonstrated in a rat model [18]. It was also supported by the behavioral testing of animals 
using FST [36], which results were reproduced in our current study as well. There is an 
immense literature of molecular changes in the rat brain underlying depression [84] and the 
question was open how neonatal clomipramine treatment could activate such a complex 
molecular network. Since there is no data about lifespan long molecular changes induced by 
chronic neonatal clomipramine administration in rats, we applied unbiased experimental 
strategy measuring protein level changes in this animal model. We predicted that 
clomipramine treatment of the flexible neonatal brain initiate a complex procedure including 
epigenetic and other brain developmental changes finally lead to depression-like phenotype in 
the adulthood. Therefore, we studied the endpoint of that predicted process experimentally. 
We can conclude that neonatally received chronic treatment with clomipramine is able to 
induce depression-like phenotype via changing the proteome and in turn the cellular 
phenotypes of cells. At the molecular level, chronic neonatal clomipramine treatment caused 
robust changes in the adult rat PFC, as 32 proteins’ levels were significantly altered in the 
CLO group. These proteins are mainly related to energy metabolism, gene expression, 
cytoskeletal organization, and immunomodulation. Comparison with the literature suggests 
that many of the changed proteins have already been related to depression but we also 
implicated new proteins in the disease. In addition, we selected MIF for further examination, 
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which showed the largest increase in response to clomipramine treatment and is involved in 
the regulation of the HPA axis. The elevated level of MIF was confirmed and its distribution 
was described in prefrontal cortical astrocytes. This protein was suggested to be involved in 
inflammatory and stress-related processes. Thus, MIF could be an important participant of the 
molecular network rearranged in depression. Further studies of MIF provide a promising new 
line of investigations to uncover molecular mechanisms of the developmental form of 
depression.  
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Figure and Table legends 
Figure 1. Graphs of the forced swim test results of the full cohort. The white columns 
represent the control (C), while the grey columns the clomipramine treated animals (CLO). 
The average time spent in each behavioral category is shown. Significant changes were found 
in the floating (p < 0.001) and struggling (p < 0.05) categories between the two groups. Mean 
± SEM is shown. * p < 0.05, *** p <0.001. 
Figure 2. Representative 2D-DIGE image of the gel with the location of numbered, 
significantly altered protein spots (n = 24). Red circles indicate increased protein level in the 
clomipramine treated group, while the blue color represents decreased proteins. 
Figure 3. Functional clustering of the significant protein changes according to UniProt 
database. Each protein is clustered in one group only, which represents its most relevant 
function. 
Figure 4. The cellular localization of the significantly changed proteins in the plasma 
membrane, mitochondrion, cytosol and nucleus. The shapes indicate the number of cellular 
locations a particular protein belongs to as follows: the oval indicates proteins in one, the 
rectangle in two, and the hexagon in three known localizations in different cellular 
compartments. Red and blue colors highlight proteins with increased and decreased levels, 
respectively. 
Figure 5. Common regulator (A) and target (B) analysis of significantly altered proteins, 
focusing on MIF connections.  
Common regulators: AGT – angiotensinogen, CABPA – CAAT/enhancer binding protein 
alpha, CREB1 – cyclic AMP-responsive element-binding protein 1, DPYSL-2 – 
dihydropyrimidinase-related protein 2, EDN1 – endothelin-1, GAPDH – glyceraldehyde-3-
phosphate dehydrogenase, GSTA-2 – glutathione S-transferase alpha-2, HIF1A – hypoxia-
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inducible factor 1-alpha, HOMER1 – homer protein homolog 1, HSPA8 – heat shock cognate 
71 kDa protein, IL1-B – interleukin-1 beta, INS – insulin, MAPK1 – mitogen-activated 
protein kinase 1, MIF – macrophage migration inhibitory factor, PGK1 – phosphoglycerate 
kinase 1, SP1 – transcription factor Sp1, TNF – tumor necrosis factor, TPI1 – triosephosphate 
isomerase, TXN – thioredoxin. 
Common targets: AGTR1 – type-1A angiotensin II receptor, BCL2 – apoptosis regulator Bcl-
2, CCL2 – C-C motif chemokine 2, CCND1 – G1/S-specific cyclin-D1, CD40LG – CD40 
ligand, CDKN1B – cyclin-dependent kinase inhibitor 1B, FOS – proto-oncogene c-Fos, 
HIF1A – hypoxia-inducible factor 1-alpha, IFNG – interferon gamma, IL1B – interleukin-1 
beta, IL2 – interleukin-2, IL2R – interleukin-2 receptor, IL2RA – interleukin-2 receptor 
subunit alpha, IL4 – interleukin-4, IL6 – interleukin-6, IL8 – interleukin-8, IL12 – interleukin-
12 subunit beta, IL13 – interleukin-13, MMP2 – 72 kDa type IV collagenase, MMP3 – 
stromelysin-1, NFKB1A – NF-kappa-B inhibitor alpha, NR3C1 – glucocorticoid receptor, 
PTGS2 – prostaglandin G/H synthase 2, TGFB1 – transforming growth factor beta-1, TNF – 
tumor necrosis factor, TP53 – cellular tumor antigen p53, VEGFA – vascular endothelial 
growth factor A. 
Figure 6. Validation of the increased protein level of MIF in the clomipramine-treated (CLO) 
group with Western blot. The MIF immunopositive band is shown at 12.5 kDa. A 1.63 ± 0.52-
fold increase (p = 0.038) in CLO group was revealed in comparison with controls (C) (n = 4 
per group) using densitometric analysis. Mean ± SEM is shown. * p < 0.05 
Figure 7. Distribution of the MIF-immunoreactivity (ir) in the prefrontal cortex (PFC).  Aa: 
The low-magnification image shows double labeling with the neuronal marker NeuN (red) 
which demonstrates different distributional pattern with MIF-ir cells (green) being most 
abundant in the upper layers where only few neurons are located. Ab: The high-magnification 
image demonstrates the lack of colocalization between MIF and NeuN. Ba: MIF (green) and 
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the astrocyte marker S100 (red) have similar distributions in all layers of the PFC. Bb: The 
high-magnification image demonstrates a high degree of colocalization between MIF- and 
S100-ir cells. Scale bars: Aa and Ba: 500 m, Ab and Bb: 100 m. 
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Table 1. Significantly increased proteins in the clomipramine treated group in comparison 
with controls. Abbreviations: Acc: accession number, AR: average ratio, SC%: sequence 
coverage percentage. The cellular location, molecular function, and biological process related 
to the proteins were also described. 
Table 2. Significantly decreased proteins in the clomipramine treated group in comparison 
with controls. Abbreviations: Acc: accession number, AR: average ratio, SC%: sequence 
coverage percentage. The cellular location, molecular function, and biological process related 
to the proteins were also described. 
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Table 1 
Spot 
No. 
Acc Gene Protein name AR p-value SC% 
Unique  
peptides Location Molecular function Biological process 
1977 P30904 MIF 
Macrophage migration 
inhibitory factor 
1.65 0.004 41 5 
Cytoplasm, 
Extracellular,  
Nucleus 
Cytokine, Isomerase 
Immunity, Inflammatory response, Innate 
immunity 
468 Q9Z214 HSPA8 
Heatshock 70 kDa protein 
8 
1.43 0.041 16 7 
Cytoplasm, 
Membrane,    
Nucleus 
Chaperone, Repressor 
Transcription, Transcription regulation, 
Stress response, mRNA processing, 
Splicing 
1367 Q5XI32 CAPZB 
F-actin-capping protein   
subunit beta 
1.37 0.021 20 
 
6 
Cytoplasm Actin capping 
Cytoskeleton organization, Neuron 
projection development, Regulation of 
cell morphogenesis 
1367 P35435 ATP5C1 
ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, gamma 
polypeptide 1 
1.37 0.021 8 
 
2 
Mitochondria 
Proton transporting, 
ATPase, synthase activity 
ATP synthesis, Hydrogen ion transport, 
Ion transport 
1998 P62078 TIMM8 
Translocase of inner 
mitochondrial membrane 
8 homolog B 
1.32 0.013 26 2 Mitochondria Chaperone Protein import 
1998 P11232 TXN Thioredoxin 1.32 0.013 22 3 
Cytoplasm,  
Extracellular, 
Nucleus 
Activator 
Transport, Electron transport, 
Transcription regulation 
1136 P68370 TUBA1A Tubulin, alpha 1 a 1.28 0.034 6 
 
3 
Cytoplasm, 
Nucleus 
GTPase activity, 
Structural constituent of 
cytoskeleton 
Microtubule based process, Protein 
polymerization 
1136 Q6AYZ1 TUBA1C Tubulin, alpha 1 c 1.28 0.034 10 3 Cytoplasm 
GTPase activity, 
Structural constituent of 
cytoskeleton 
Microtubule based process, Protein 
polymerization 
1136 Q5XIF6 TUBA4A Tubulin, alpha 4 a 1.28 0.034 10 3 Cytoplasm 
GTPase activity, 
Structural constituent of 
cytoskeleton 
Microtubule based process, Protein 
polymerization 
1546 P48500 TPI1 
Triosephosphate 
isomerase 1 
1.25 0.009 16 3 
Cytoplasm, 
Nucleus 
Isomerase 
Gluconeogenesis, Glycolysis, Pentose 
shunt 
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1546 P04903 GSTA2 
GlutathioneS-transferase 
A2 
1.25 0.009 17 4 
Cytoplasm, 
Membrane, 
Nucleus 
Glutathione transferase 
activity, Drug binding 
Aging, Xenobiotic catabolic process, 
Detoxification 
1799 P62870 TCEB2 
Transcription elongation 
factor B (SIII), polypeptide 
2 (18 kDa, elongin B) 
1.24 0.046 27 4 Nucleus 
Protein complex binding, 
Transcription coactivator 
activity 
Transcription, Transcription regulation, 
Ubl conjugation pathway 
1061 Q5RKH2 GALK1 Galactokinase 1 1.11 0.043 27 8 
Cytoplasm, 
Membrane, 
Extracellular 
Kinase 
Carbohydrate phosphorylation, Galactose 
metabolic process 
1217 O88989 MDH1 Malate dehydrogenase 1 1.19 0.015 5 2 
Cytoplasm, 
Mitochondria 
Oxidoreductase Tricarboxylic acid cycle 
1217 Q566Q8 Bles03 
UPF0696 protein C11orf68 
homolog 
1.19 0.015 11 2 NA NA NA 
1357 P85973 NP Nucleoside phosphorylase 1.18 0.044 10 2 
Cytoplasm, 
Extracellular,  
Nucleus 
Glycosyltransferase, 
Transferase 
Purine nucleoside metabolic process 
880 Q9Z214 HOMER1 Homer protein homolog 1 1.17 0.041 23 7 
Cytoplasm, 
Membrane 
Receptor, Scaffold 
protein binding, Protein 
complex 
Protein localization to synapse, Response 
to calcium 
880 P07335 CKB Creatine kinase 1.17 0.041 39 9 
Cytoplasm, 
Mitochondria,  
Membrane 
Kinase, Transferase 
Phosphocreatine metabolic process, 
Cellular chloride ion homeostasis 
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Table 2 
Spot No. Acc Gene Protein name AR p-value SC%    
Unique 
peptides Location 
Molecular 
function 
Biological process 
919 P16617 PGK1 
Phosphoglycerate 
kinase 1 
-1.34 0.040 11  3 Cytoplasm 
Kinase, 
Transferase 
Glycolysis 
919 B3GNI6 SEPT11 Septin 11 -1.34 0.040 7 2 
Cytoplasm, 
Extracellular 
GTP binding Cell cycle, Cell division 
254 
Q9ER34 ACO2 Aconitase 2 
-1.33 0.041 30 19 Mitochondria, 
Nucleus 
Lyase Tricarboxylic acid cycle 
268 -1.19 0.048 30 22 
1551 B0BNE6 NDUFS8 
NADH dehydrogenase 
Fe-S protein 8 
(predicted) 
-1.23 0.011 20 5 Mitochondria 
NADH 
dehydrogenase 
activity 
Mitochondrial respiratory chain 
complex I assembly 
1551 Q6AXU6 HN1 
Hematological and 
neurological 
expressed 1 
-1.23 0.011 19 2 Nucleus NA Developmental process 
469 
P47942 DPYSL2 
Dihydropyrimidinase-
like 2 
-1.21 0.037 6 3 
Cytoplasm, 
Membrane 
Hydrolase Differentiation, Neurogenesis 554 -1.16 0.005 22 10 
573 -1.13 0.020 9 4 
1445 Q5XI72 EIFH4 
Eukaryotic translation 
initiation factor 4H 
-1.18 0.043 14 3 
Cytoplasm, 
Membrane 
Protein 
synthesis 
Translation 
554 O35814 STIP1 
Stress-induced-
phosphoprotein 
(Hsp70/Hsp90-
organizing protein) 
-1.16 0.005 4 
 
2 
 
Cytoplasm, 
Nucleus 
Chaperone 
binding 
Response to stress 
1796 P02401 RPLP2 
Ribosomal protein, 
large, P2 
-1.15 0.039 50 
 
7 
 
Cytoplasm 
Structural 
constituent of 
ribosome 
Translation elongation 
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1506 P04797 GAPDH 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
-1.11 0.009 15 3 
Cytoplasm, 
Nucleus 
Oxydoreductase, 
Transferase 
Apoptosis, Glycolysis, 
Translation regulation 
1577 P63029 TPT1 
Tumor protein 
translationally-
controlled 1 
-1.1 0.027 34 7 Cytoplasm 
Ca binding – 
Microtubule 
stabilization 
Cell proliferation, 
Spermatogenesis 
1252 B4F7C2 TUBB4 Tubulin, beta 4/5 -1.1 0.038 19 6 
Cytoplasm, 
Extracellular 
GTPase activity, 
Structural 
constituent of 
cytoskeleton 
Microtubule based process, 
Protein polymerization 
1252 P49432 PDHB 
Pyruvate 
dehydrogenase 
(lipoamide) beta 
-1.1 0.038 38 14 Mitochondria Oxidoreductase 
Carbohydrate, Glucose 
metabolism, Tricarboxylic acid 
422 P48721 HSPA9 
Heatshock 70 kDa 
protein 9 (mortalin) 
-1.08 0,009 34 4 
Cytoplasm, 
Mitochondria,  
Nucleus 
Chaperone ATP-binding, Nucleotide-binding 
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Highlights 
 Chronic neonatal clomipramine treatment induces depression-like symptoms in rats 
 Altered levels of 32 proteins have been revealed in the prefrontal cortex of rats 
 The macrophage migration inhibitory factor (MIF) showed the largest alteration  
 MIF is predominantly expressed in astrocytes  
 Inflammation-associated mechanisms are suggested in this model 
